Business Context and Reporting Period
This Form 8-K Current Report is filed by Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) on May 21, 2025, regarding events occurring on May 19, 2025. The filing addresses significant changes in the Company's executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide updated revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial data disclosed relates to executive compensation:
- Base Salary: The new Chief Financial Officer, Steven Coen, will receive an annual base salary of $460,000.
- Equity Award: Mr. Coen will receive 67,991 performance-based restricted stock units (PSUs).
- Performance Condition: The PSU award vests based on the achievement of 2025 Company-wide planned cash flow objectives over the period of January 1, 2025, to December 31, 2025.
Material Changes Versus Prior Period
The primary material change reported is the transition of the Chief Financial Officer role:
- Resignation: Mark Dmytruk, the former Chief Financial Officer and principal financial officer, resigned effective May 30, 2025, to accept a position at another organization.
- Appointment: Steven Coen, CPA, formerly the Chief Accounting Officer, was appointed as the new Chief Financial Officer, principal financial officer, and principal accounting officer effective upon Mr. Dmytruk's resignation.
Guidance, Outlook, and Management Commentary
The filing references the Company's 2025 planned cash flow objectives as the metric for the new CFO's equity vesting but does not disclose specific numerical guidance or targets. The Compensation Committee previously set these objectives. No other risks, contingencies, or unusual items are detailed in this specific report beyond the leadership transition.
Important Facts for Investor Verification
- Verify the specific numerical targets for the "2025 Company-wide planned cash flow objectives" referenced in the new CFO's compensation package, as these are not explicitly stated in this filing.
- Confirm the exact effective date of the leadership transition (May 30, 2025) and any interim arrangements for financial reporting between the filing date and the effective date.
- Review the standard form of indemnification agreement referenced in the filing to understand the liability protections for the new CFO.
- Monitor subsequent filings for any impact of this leadership change on the Company's financial reporting or strategic direction.